Cargando…

Genome-wide association study and polygenic risk score analysis of esketamine treatment response

To elucidate the genetic underpinnings of the antidepressant efficacy of S-ketamine (esketamine) nasal spray in major depressive disorder (MDD), we performed a genome-wide association study (GWAS) in cohorts of European ancestry (n = 527). This analysis was followed by a polygenic risk score approac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Qingqin S., Wajs, Ewa, Ochs-Ross, Rachel, Singh, Jaskaran, Drevets, Wayne C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387452/ https://www.ncbi.nlm.nih.gov/pubmed/32724131 http://dx.doi.org/10.1038/s41598-020-69291-6

Ejemplares similares

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD
por: Williamson, David, et al.
Publicado: (2022)

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study
por: Morrison, Randall L., et al.
Publicado: (2018)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
por: Doherty, Teodora, et al.
Publicado: (2020)

Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data
por: Nijs, Michel, et al.
Publicado: (2020)

Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
por: Doty, Richard L., et al.
Publicado: (2021)

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
por: Jamieson, Carol, et al.
Publicado: (2023)

Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials
por: Saad, Ziad, et al.
Publicado: (2020)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
por: Floden, Lysbeth, et al.
Publicado: (2022)

Phenome-wide analysis of genome-wide polygenic scores
por: Krapohl, E, et al.
Publicado: (2016)

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2020)

A flexible and parallelizable approach to genome‐wide polygenic risk scores
por: Newcombe, Paul J., et al.
Publicado: (2019)

Meta-analysis of epigenome-wide association studies of major depressive disorder
por: Li, Qingqin S., et al.
Publicado: (2022)

Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression
por: Guo, Wei, et al.
Publicado: (2018)

Genome-wide polygenic risk score for type 2 diabetes in Indian population
por: Pemmasani, Sandhya Kiran, et al.
Publicado: (2023)

Improved prediction of fracture risk leveraging a genome-wide polygenic risk score
por: Lu, Tianyuan, et al.
Publicado: (2021)

Correction: Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression
por: Guo, Wei, et al.
Publicado: (2019)

Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians
por: Wünnemann, Florian, et al.
Publicado: (2019)

An Improved Genome-Wide Polygenic Score Model for Predicting the Risk of Type 2 Diabetes
por: Liu, Wei, et al.
Publicado: (2021)

Development and Replication of a Genome-Wide Polygenic Risk Score for Chronic Back Pain
por: Tsepilov, Yakov A., et al.
Publicado: (2023)

The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study
por: van de Loo, Aurora J. A. E., et al.
Publicado: (2017)

Stability of polygenic scores across discovery genome-wide association studies
por: Schultz, Laura M., et al.
Publicado: (2022)

Derivation and Validation of Genome‐Wide Polygenic Score for Ischemic Heart Failure
por: Paranjpe, Ishan, et al.
Publicado: (2021)

Genome-Wide Polygenic Risk Score for Predicting High Risk Glaucoma Individuals of Han Chinese Ancestry
por: Hsiao, Yu-Jer, et al.
Publicado: (2021)

Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
por: Khera, Amit V., et al.
Publicado: (2018)

Contribution of Genome-Wide Polygenic Score to Risk of Coronary Artery Disease in Childhood Cancer Survivors
por: Sapkota, Yadav, et al.
Publicado: (2022)

Getting the Most Out of Your Genome-Wide Association Study Using Polygenic Risk Scores
por: Maggioncalda, Emily, et al.
Publicado: (2023)

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
por: Zaki, Naim, et al.
Publicado: (2023)

Generalisation of genomic findings and applications of polygenic risk scores
por: Corpas, Manuel, et al.
Publicado: (2023)

Genome-Wide Polygenic Scores Predict Reading Performance Throughout the School Years
por: Selzam, Saskia, et al.
Publicado: (2017)

Fine-tuning of Genome-Wide Polygenic Risk Scores and Prediction of Gestational Diabetes in South Asian Women
por: Lamri, Amel, et al.
Publicado: (2020)

A genome-wide association and polygenic risk score study on abnormal electrocardiogram in a Chinese population
por: Wang, Mengqiao, et al.
Publicado: (2021)

Association of Genome-Wide Polygenic Scores for Multiple Psychiatric and Common Traits in Preadolescent Youths at Risk of Suicide
por: Joo, Yoonjung Yoonie, et al.
Publicado: (2022)

Genome-wide association study meta-analysis of suicide death and suicidal behavior
por: Li, Qingqin S., et al.
Publicado: (2022)

The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
por: Daly, Ella J., et al.
Publicado: (2021)

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
por: Fedgchin, Maggie, et al.
Publicado: (2019)

Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine
por: Borentain, Stephane, et al.
Publicado: (2022)

The effect of heteroscedasticity on the prediction efficiency of genome-wide polygenic score for body mass index
por: Baek, Eun Ju, et al.
Publicado: (2022)

Polygenic transcriptome risk scores (PTRS) can improve portability of polygenic risk scores across ancestries
por: Liang, Yanyu, et al.
Publicado: (2022)

Genome‐wide pleiotropy analysis identifies novel blood pressure variants and improves its polygenic risk scores
por: Zhu, Xiaofeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kk7nq53j924njlm1kfej54q0cf